Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 148 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Fibroblasts Clear all

Conditions: Primary Immunodeficiency, DOCK8, Virus Susceptibility
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
Interventions: Futibatinib, Futibatinib plus Fulvestrant; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Phoenix, Arizona • San Francisco, California • Fort Myers, Florida + 12 more

Conditions: Chronic Kidney Diseases, Chronic Heart Failure, Iron Deficiency Anemia
Interventions: Iron Sucrose; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Solid Tumor
Interventions: OMTX705, Pembrolizumab, Tislelizumab (BGB-A317); Drug
Lead sponsor: Oncomatryx Biopharma S.L.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non Small Cell Lung Cancer (NSCLC)
Interventions: semi-allogeneic human fibroblasts (MRC-5) transfected with DNA; Biological
Lead sponsor: Theresa Whiteside, PhD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Interventions: Pemigatinib, Gemcitabine, Cisplatin; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 36
States / cities: Phoenix, Arizona • Greenbrae, California • Orange, California + 29 more

Conditions: Albuminuria
Interventions: Higher phosphorus period, Lower phosphorus period; Other
Lead sponsor: Geisinger Clinic; Other
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fibrosis (Morphologic Abnormality)
Interventions: [F-18]-FAPI-74; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epidermolysis Bullosa
Interventions: ABH001, Control wound treatment; Biological · Other
Lead sponsor: Shire Regenerative Medicine, Inc.; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Phoenix, Arizona • Redwood City, California • San Diego, California + 3 more

Conditions: Cancer
Interventions: Lenvatinib; Drug
Lead sponsor: Teresa Helsten, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: La Jolla, California • Chicago, Illinois

Conditions: Metastatic Melanoma
Interventions: RO6874281, Pembrolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: New Haven, Connecticut • Iowa City, Iowa • Boston, Massachusetts

Conditions: Neoplasms
Interventions: Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Cancer, Skin Fibroblasts, Muscle Weakness
Interventions: Nicotinamide Riboside (NR); Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Wounds and Injuries
Interventions: autologous skin fibroblasts, Filler Product; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Interventions: [68Ga]FAPI-46; Drug
Lead sponsor: SOFIE; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Los Angeles, California • Grand Rapids, Michigan • Rochester, Minnesota + 1 more

Conditions: Solid Tumor, Breast Cancer, Cancer of Head and Neck
Interventions: RO6874281, Trastuzumab, Cetuximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 5
States / cities: Tucson, Arizona • La Jolla, California • Greeley, Colorado + 2 more

Conditions: Kidney Disease
Interventions: Lanthanum Carbonate, 900 mg Phosphate Diet, LC Placebo, Ad Libitum Diet; Drug · Other
Lead sponsor: Myles Wolf; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Restrictive Burn Scars
Interventions: Autologous fibroblasts, placebo sterile saline; Biological
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 9
States / cities: Sacramento, California • San Diego, California • Miami, Florida + 6 more

Conditions: Advanced Chronic Liver Disease, Healthy Participants
Interventions: AZD2389, Quinidine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: X-linked Hypophosphatemia, Hypophosphatemic Rickets
Interventions: No intervention; Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: Not listed
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Autism, Tuberous Sclerosis
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 4 Years to 18 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: University of Kentucky; Other
Eligibility: 40 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: MPN (Myeloproliferative Neoplasms)
Interventions: Pemigatinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 9
States / cities: Phoenix, Arizona • Duarte, California • Stanford, California + 6 more

Search by objective public record fields.

Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Iron Deficiency and FGF23 Regulation in CKD and HF

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23

FAPI-74 PET/CT in Adults With Fibrosis

A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

Feasibility Study for Fibroblast Autologous Skin Grafts

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)

Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

X-linked Hypophosphatemia Disease Monitoring Program

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

Studies of Autistic Patients: Gene Networks and Clinical Subtypes

A Pilot Feasibility Study of Fibroblast Calcium and Glucoregulation in Health and Disease

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)